Table 6 Summary of studies assessing the prognostic value of cyclin D1 in OTSCC providing unadjusted or adjusted estimates of HR and their 95% confidence intervals for one or more endpoints, the HRs contrasting positive to negative expression
From: Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis
(Authors, Year) Country | Stage or tumour size (primary treatment) | Primary antibody | Cutoff point in percentage | No. of cases | No. of Positive cases (%) | Endpoint | Unadjusted analysis | Adjusted analysis | Compliance to REMARK guidelines |
|---|---|---|---|---|---|---|---|---|---|
(Bova et al, 1999) Australia | I–IV (S in 96 patients; S with adjuvant RT in 52 patients) | NCL-cyclin D1-GM, monoclonal (1 : 50; Novocastra, Rockdale, Australia) | 10 | 147 | 100 (68) | OS | HR 3.89 (95% CI 1.37–11.07), P=0.01 | HR 4.2 (95% CI 1.23–14.09), P=0.02 | Fulfilled items summarised in Table 1 |
DFS | HR 2.50 (95% CI 1.32–5.15), P=0.006 | HR 2.48 (95% CI 1.0–6.15), P=0.05 | |||||||
(Trivedi et al, 2011) India | T1–T4 (S followed by RT in 26 cases, CT in 1 case, RT with CT in 5 cases) | P2D11F11, monoclonal, (dilution 1 : 50; Novocastra laboratories, Newcastle, UK) | 10 | 61 | 25 (41) | OS | HR 2.20 (95% CI 0.85–5.70) P=0.103 | NA | Checklist no. 5 was not fulfilled |
RFS | HR 1.91 (95% CI 0.84–4.38), P=0.122 | NA |
